These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. New experimental approaches to reducing carcinogenicity in animals by modifying regimens. Habs M; Schmähl D IARC Sci Publ; 1986; (78):177-85. PubMed ID: 3108155 [No Abstract] [Full Text] [Related]
4. Recent developments in cancer chemotherapy. Jewers K Prog Drug Res; 1981; 25():275-360. PubMed ID: 7031765 [No Abstract] [Full Text] [Related]
5. Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Farrell N Met Ions Biol Syst; 1996; 32():603-39. PubMed ID: 8640533 [No Abstract] [Full Text] [Related]
6. [Pharmacologic studies with trophosphamide (Ixoten), a new oxazaphosphorineoxide]. Brock N Med Monatsschr; 1973 Sep; 27(9):390-4. PubMed ID: 4768197 [No Abstract] [Full Text] [Related]
7. Structure-activity relationships in the carcinogenicity of anticancer agents. Prejean JD; Montgomery JA Drug Metab Rev; 1984; 15(3):619-46. PubMed ID: 6386411 [No Abstract] [Full Text] [Related]
8. The mechanisms of action of antitumor compounds. Belousova AK Natl Cancer Inst Monogr; 1977 Mar; (45):183-93. PubMed ID: 73135 [No Abstract] [Full Text] [Related]
9. Test for carcinogenicity of food additives and chemotherapeutic agents by the pulmonary tumor response in strain A mice. Stoner GD; Shimkin MB; Kniazeff AJ; Weisburger JH; Weisburger EK; Gori GB Cancer Res; 1973 Dec; 33(12):3069-85. PubMed ID: 4202501 [No Abstract] [Full Text] [Related]
10. Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas. Wheeler GP; Bowdon BJ; Grimsley JA; Lloyd HH Cancer Res; 1974 Jan; 34(1):194-200. PubMed ID: 4809457 [No Abstract] [Full Text] [Related]
11. [Nephrotoxicity of anti-tumor agents]. Guelpa G Schweiz Rundsch Med Prax; 1985 May; 74(22):581-2. PubMed ID: 3925523 [No Abstract] [Full Text] [Related]
12. [STUDIES ON ANTITUMOR DRUGS. III. THE USE OF IN VITRO CULTURE OF YOSHIDA ASCITES SARCOMA CELLS IN SCREENING ANTITUMOR SUBSTANCES]. CHU TH; WU YI Yao Xue Xue Bao; 1963 Jun; 10():334-44. PubMed ID: 14070616 [No Abstract] [Full Text] [Related]
14. [Structure-activity relationship in Mannich bases with and without nitrogen mustard groups and in various reduction products derived from beta-aminoketones as evidenced with the aid of a cancerostatic 3-step test using transplantation tumors]. Werner W; Jungstand W; Gutsche W; Wohlrabe K Pharmazie; 1977 Jun; 32(6):341-7. PubMed ID: 896938 [No Abstract] [Full Text] [Related]
15. Effect of antitumor platinum compounds with trans geometry on the induction of cytotoxicity and cell cycle modifications. Barletta A; Coluccia M; Nassi A; Pardiso A Eur J Histochem; 1997; 41 Suppl 2():61-2. PubMed ID: 9859784 [No Abstract] [Full Text] [Related]
16. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Plooy AC; van Dijk M; Lohman PH Cancer Res; 1984 May; 44(5):2043-51. PubMed ID: 6538808 [TBL] [Abstract][Full Text] [Related]
17. Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms. Marples B; Adomat H; Billings PC; Farrell NP; Koch CJ; Skov KA Anticancer Drug Des; 1994 Oct; 9(5):389-99. PubMed ID: 7945723 [TBL] [Abstract][Full Text] [Related]
18. Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Bloemink MJ; Reedijk J Met Ions Biol Syst; 1996; 32():641-85. PubMed ID: 8640534 [No Abstract] [Full Text] [Related]
19. [Immunosuppressive effect of various cytostatics on humoral antibody formation]. Potel J; Brock N Arzneimittelforschung; 1971 Aug; 21(8):1250-4. PubMed ID: 5110029 [No Abstract] [Full Text] [Related]